Brief: Theravance Biopharma Expects To Complete Pifr-2 Study And Provide Top-Line Results In 2H 2023
09/01/2023 11:52
Jan 9 (Reuters) - Theravance Biopharma Inc TBPH.O :
* THERAVANCE BIOPHARMA INC - EXPECTS TO COMPLETE PIFR-2
STUDY AND
PROVIDE TOP-LINE RESULTS IN 2H 2023
* THERAVANCE BIOPHARMA INC - EXPECTS TO GENERATE NON-GAAP
PROFIT
IN 2H 2023
Source text for Eikon: ID:nPn23pvtJa
Further company coverage: TBPH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Theravance Biopharma
See all newsIreland's Theravance Biopharma Q1 revenue beats estimates on YUPELRI growth
Ireland's Theravance Biopharma Q4 revenue misses expectations
Corrected: BRIEF-Theravance Biopharma Q4 Operating Income USD 20.012 Million
U.S. STOCKS ON THE MOVE-Versant Media Group, Lithium miners, Expedia Group
U.S. STOCKS ON THE MOVE-Expedia Group, Blue Owl Capital, Enphase Energy